MERSANA THERAPEUTICS, INC. (MRSN)

[jaybe]

Exactly. Looking forward to pre-clinical on next ADC in November at ENA18.

Also should see next-gen platform (payload/linker) presentation at same conference.

Takeda selected ADC will move more slowly, wouldn't be surprised if we don't see data until next year at AACR19.

All eyes on Wednesday 5PM...first clinical data for XMT-1536, sets the table for all science.

DS-8201 showing 60% ORR in Her2+ and 30% ORR in Her-low, those are the benchmarks for a competitive next-gen ADC in MBC.